Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
2,189
datasets available to search
ShareScore release 0.9.0
Dataset results
2,189 results for “AML”
Cladribine, Cytarabine and Idarubicin in Patients With Relapsed Acute Myelocytic Leukemia (AML)
ClinicalTrials.gov study NCT00126321. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Maintenance Therapy in Acute Myeloid Leukemia (AML) Patients
ClinicalTrials.gov study NCT00957385. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Ficlatuzumab With High Dose Cytarabine in Relapsed and Refractory AML
ClinicalTrials.gov study NCT02109627. IPD Sharing: NO. Countries: 1. Publications: 0.
Phase II Trial in Elderly Patients With AML or MDS in Complete Remission Not Eligible for Allogenic Transplant
ClinicalTrials.gov study NCT03961919. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT07008638. IPD Sharing: Not stated. Countries: 1. Publications: 0.
RWE of 1st Line Treatment in Adults With AML From 18 to 70 Years Old.
ClinicalTrials.gov study NCT05127798. IPD Sharing: YES. Countries: 1. Publications: 0.
Relatlimab With Nivolumab and 5-Azacytidine for the Treatment of AML
ClinicalTrials.gov study NCT04913922. IPD Sharing: NO. Countries: 1. Publications: 0.
Lenalidomide Plus Chemotherapy for AML
ClinicalTrials.gov study NCT01681537. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Prospective Non-interventional Study of Adult Patients With Acute Myeloid Leukemia (AML)
ClinicalTrials.gov study NCT04777916. IPD Sharing: Not stated. Countries: 1. Publications: 0.
NK Cell Infusion for Remission Consolidation in AML: A Phase II Trial
ClinicalTrials.gov study NCT06783478. IPD Sharing: UNDECIDED. Countries: 1. Publications: 0.
Sorafenib to Treat FLT3-ITD AML
ClinicalTrials.gov study NCT02156297. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Evaluation of Treosulfan Versus Melphalan Conditioning Followed by PTCy in Patients With AML and MDS Undergoing Allogeneic Transplantation
ClinicalTrials.gov study NCT07025824. IPD Sharing: Not stated. Countries: 1. Publications: 0.
HM2023-05: GTB-3650 Trike for High Risk MDS and R/R AML
ClinicalTrials.gov study NCT06594445. IPD Sharing: Not stated. Countries: 1. Publications: 0.
A Clinical Trial to Evaluate Clifutinib in Patients with Relapsed or Refractory Acute Myeloid Leukemia(AML)
ClinicalTrials.gov study NCT04827069. IPD Sharing: Not stated. Countries: 1. Publications: 0.
Combination of Sorafenib and Omacetaxine Mepesuccinate in Newly Diagnosed or Relapsed/Refractory AML Carrying FLT3-ITD
ClinicalTrials.gov study NCT03170895. IPD Sharing: NO. Countries: 1. Publications: 0.
A Study of TSC-100 and TSC-101 in AML, ALL and MDS in Patients Undergoing Allogeneic Peripheral Blood Stem Transplantation
ClinicalTrials.gov study NCT05473910. IPD Sharing: NO. Countries: 1. Publications: 0.
Chemotherapy Followed by Infusion of Partially HLA Matched Unrelated Donor Cells for Patients With AML Who Are Ineligible for Stem Cell Transplantation
ClinicalTrials.gov study NCT02189824. IPD Sharing: Not stated. Countries: 1. Publications: 0.
The Role of Allo-HSCT in MRD-negative Patients With AML Under the Age of 60 Years in the First Complete Remission
ClinicalTrials.gov study NCT05339204. IPD Sharing: YES. Countries: 1. Publications: 0.
Venetoclax-Enhanced BUCY vs. Standard BUCY Conditioning in High-Risk AML and MDS Patients Undergoing Allo-HSCT (Ven-BUCY Study)
ClinicalTrials.gov study NCT07183878. IPD Sharing: YES. Countries: 1. Publications: 0.
Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT
ClinicalTrials.gov study NCT05015426. IPD Sharing: Not stated. Countries: 1. Publications: 0.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.